Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
BuChE Inhibitor
BuChE-IN-12 is a selective butyrylcholinesterase (BuChE) inhibitor with an IC50 of 0.52 µM, targeting the catalytic and peripheral anionic sites. This compound has demonstrated potential against oxidative stress, making it valuable for exploring therapeutic approaches in Alzheimer's disease research. BuChE-IN-12 serves as a useful tool for investigating the role of BuChE in neurotransmission and related neurodegenerative conditions. -
BChE Inhibitor
S21-1011 is a selective inhibitor of butyrylcholinesterase (BChE) with IC50 values of 0.059 μM for equine BChE and 0.162 μM for human BChE. This compound demonstrates effective blood-brain barrier permeability and favorable pharmacokinetic properties. Additionally, S21-1011 exhibits anti-inflammatory activity by activating the keap1-Nrf2-ARE signaling pathway, with an EC50 of 23.48 μM for antioxidant response element activation. Its potential to ameliorate cognitive impairments in murine models of Alzheimer’s disease makes it relevant for neurodegenerative research applications. -
AChE Inhibitor
AChE-IN-17 is a potent acetylcholinesterase (AChE) inhibitor with an IC50 value of 28.98 μM. This compound demonstrates significant neuroprotective effects by preventing hydrogen peroxide-induced cell death in PC12 cells. AChE-IN-17 is valuable for research focused on neurodegenerative diseases, providing insights into therapeutic strategies for conditions characterized by cholinergic dysfunction. -
AChE Inhibitor
AChE-IN-6 is a potent acetylcholinesterase (AChE) inhibitor, exhibiting significant inhibitory activity against both eel AChE (IC50 = 0.20 μM) and human AChE (IC50 = 37.02 nM). Additionally, AChE-IN-6 demonstrates robust anti-amyloid beta activity, with IC50 values of 1.92 μM for inhibiting self-induced Aβ1-42 aggregation and 1.80 μM for promoting disaggregation of Aβ1-42 fibrils. These properties suggest its utility in Alzheimer's disease research, particularly in exploring therapeutic strategies targeting cholinergic dysfunction and amyloid pathology. -
Cholinesterase Inhibitor
BChE-IN-45 is a competitive cholinesterase inhibitor designed to target butyrylcholinesterase (BChE) and acetylcholinesterase (AChE). It demonstrates an inhibition constant (Ki) of 11.13 μM for dual action, with IC50 values of 13.8 μM for BChE and 35.63 μM for AChE. BChE-IN-45 is a valuable tool for research focused on neurodegenerative conditions, particularly Alzheimer's disease, enabling the exploration of cholinergic system modulation. -
AChE/BChE Inhibitor
AChE/BChE-IN-11 is a potent dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), with IC50 values of 70 μM and 71 μM, respectively. This natural product, derived from artichoke leaves, exhibits significant biological activity relevant to neurodegenerative disorders. AChE/BChE-IN-11 can be utilized in studies investigating Alzheimer's disease and other conditions linked to cholinergic dysfunction, facilitating the exploration of therapeutic options targeting cholinesterase enzymes. -
AChE/BuChE Inhibitor
AChE/BuChE-IN-1 is a selective butyrylcholinesterase (BuChE) inhibitor that exhibits an IC50 of 0.48 μM for BuChE and 7.16 μM for acetylcholinesterase (AChE). This compound demonstrates significant scavenging activity against reactive oxygen species (·OH) with an IC50 of 0.1674 μM and effectively inhibits Aβ1-42 aggregation under various conditions (self-, Cu2+-induced, AChE-induced). With high blood-brain barrier permeability and bioavailability, alongside low cytotoxicity, AChE/BuChE-IN-1 is valuable for research into Alzheimer’s disease pathophysiology and therapeutic strategies. -
AChE Inhibitor
Acotiamide hydrochloride is a selective and reversible inhibitor of acetylcholinesterase (AChE), exhibiting an IC50 of 1.79 μM. This compound is known to enhance gastric contractility and promote accelerated gastric emptying. Acotiamide hydrochloride is primarily utilized in research focused on functional dyspepsia related to gastric motility dysfunction and intestinal inflammation. -
Acetylcholinesterase Inhibitor
Eseramine is a weak acetylcholinesterase inhibitor with an IC50 value of 9300 nM. Its primary mechanism involves the modulation of acetylcholinesterase activity, making it relevant for research into conditions such as glaucoma, myasthenia gravis, and organophosphate poisoning-related protection. Eseramine serves as a valuable tool in the exploration of therapeutic strategies targeting acetylcholinesterase regulation in various neurological disorders. -
AChE Inhibitor
AChE-IN-92 is a highly selective acetylcholinesterase (AChE) inhibitor with an IC50 of 4.6 nM. By inhibiting AChE activity, it effectively prevents the hydrolysis of acetylcholine, leading to increased synaptic levels of this neurotransmitter. AChE-IN-92 is a valuable tool for research focusing on Alzheimer’s disease and related neurodegenerative disorders. -
Acetylcholinesterase Inhibitor
AChE-IN-113 is a selective inhibitor of acetylcholinesterase, exhibiting a Ki value of 8.3 μM against electric eel acetylcholinesterase. This compound is utilized in research focused on Alzheimer's disease, allowing for the investigation of cholinergic signaling pathways and the potential therapeutic implications in neurodegeneration. Its specificity for acetylcholinesterase makes it a valuable tool for studying enzyme activity and related disorders. -
Cholinesterase (ChE) Inhibitor
Picfeltarraenin IV is a triterpenoid compound that acts as an acetylcholinesterase (AChE) inhibitor. This compound exhibits significant potential for modulating cholinergic neurotransmission, making it relevant for studies related to neurological conditions. Additionally, Picfeltarraenin IV demonstrates biological activities that may be beneficial in the treatment of herpes infections, cancer, and inflammatory disorders. Its diverse therapeutic applications make it a valuable reagent for research in pharmacology and medicinal chemistry. -
AChE Inhibitor
Chondrocurine, an alkaloid derived from the roots of Cissampelos pareira Linn., functions as an acetylcholinesterase (AChE) inhibitor with an IC50 of 7.46 μM. This compound demonstrates significant activity in modulating cholinergic signaling, making it a valuable tool for studying neuropharmacology and related fields. Its application in research may extend to investigations of neurodegenerative diseases and neuromuscular junction disorders. -
AChE/BChE/MAO-B Inhibitor
AChE/BChE/MAO-B-IN-5 is a multitarget inhibitor of acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and monoamine oxidase B (MAO-B). With IC50 values of 0.24 µM, 6.29 µM, and 0.11 µM for AChE, BChE, and MAO-B, respectively, this compound demonstrates potent inhibition of key enzymes involved in cholinergic neurotransmission and monoamine metabolism. AChE/BChE/MAO-B-IN-5 is particularly relevant for research into neurodegenerative diseases, including Alzheimer's disease, due to its ability to penetrate the blood-brain barrier. -
AChE Inhibitor
2-Hydroxyalbrassitriol is a potent inhibitor of acetylcholinesterase (AChE) with an IC50 of 35.97 μM. This compound is utilized in research focused on neurodegenerative diseases and cognitive function by modulating cholinergic signaling. Its inhibition of AChE makes it a valuable reagent for studies investigating potential therapeutic strategies for conditions such as Alzheimer's disease. -
BChE Inhibitor
BChE-IN-5 is a selective inhibitor of butyrylcholinesterase (BChE) with an IC50 of 2.8 nM, demonstrating greater potency against human BChE compared to human acetylcholinesterase (hAChE). This compound is valuable for research focused on neurodegenerative disorders, particularly Alzheimer's disease, by modulating cholinergic signaling pathways. Its specificity and efficacy make BChE-IN-5 a significant tool in elucidating the role of BChE in cognitive decline and related pathologies. -
AChE Inhibitor
Stacofylline is a potent inhibitor of acetylcholinesterase (AChE), exhibiting an IC50 range of 5-50 nM. This xanthine derivative demonstrates significant anti-amnesic and promnesic properties, making it a valuable compound for research involving cognitive enhancement and memory-related studies. Its ability to modulate cholinergic neurotransmission highlights its potential applications in neuropharmacology and the investigation of Alzheimer's disease and other memory disorders. -
AChE Inhibitor
8-Hydroxydihydrochelerythrine is a selective and competitive inhibitor of acetylcholinesterase (AChE) with an IC50 of 0.61 μM. Derived from the roots of Zanthoxylum nitidum, this benzophenanthridine alkaloid enhances acetylcholine levels in cholinergic synapses, thereby facilitating improved cholinergic neurotransmission. Its unique mechanism makes 8-Hydroxydihydrochelerythrine valuable for research into neurodegenerative disorders, particularly Alzheimer's disease and related dementias. -
AChE/BChE Inhibitor
AChE/BChE-IN-2 is a potent inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), exhibiting IC50 values of 0.96 ± 0.14 µM for AChE and 1.23 ± 0.23 µM for BChE. This compound is valuable for research into Alzheimer's disease and other neurodegenerative disorders, facilitating studies on cholinergic signaling and enzyme activity modulation. Its efficacy in inhibiting cholinesterases makes it a significant tool for understanding the biochemical pathways involved in cognitive decline. -
AChE/BChE Inhibitor
AChE/BChE-IN-6 is a potent dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), exhibiting IC50 values of 0.809 µM for AChE and 2.248 µM for BChE, with limited activity against hMAO-B. This compound effectively penetrates the blood-brain barrier, making it a valuable tool for research focused on Alzheimer's disease. Its ability to inhibit cholinesterases suggests potential applications in studies aiming to understand and develop treatments for neurodegenerative conditions characterized by cholinergic dysfunction. -
AChE Inhibitor
AChE-IN-24 is a potent inhibitor of acetylcholinesterase (AChE), demonstrating remarkable ability to penetrate the blood-brain barrier. It exhibits strong inhibitory activity against human AChE, with an IC50 value of 0.053 μM. This compound is valuable for research in Alzheimer's disease, facilitating studies aimed at understanding the enzymatic mechanisms involved in neurodegeneration. -
AChE Inhibitor
Artanin is a coumarin derivative that functions as an acetylcholinesterase (AChE) inhibitor. It demonstrates significant biological activities relevant to Alzheimer's disease, including the inhibition of AChE and the prevention of amyloid beta (Aβ) aggregation, with IC50 values of 51 μM, 98 μM, and 124 μM, respectively. This compound is valuable for research focusing on neurodegenerative disorders and the mechanistic exploration of Alzheimer's pathology. -
sEH/AChE Inhibitor
sEH/AChE-IN-2 is a dual inhibitor targeting soluble epoxide hydrolase (sEH) and acetylcholinesterase (AChE). This compound demonstrates significant potential in mitigating neuroinflammation and addressing memory impairment. Its dual inhibitory action provides a valuable tool for investigating therapeutic strategies in Alzheimer's disease research. -
AChE/BuChE/MAO-B Inhibitor
AChE/BuChE/MAO-B-IN-1 is a potent inhibitor of human acetylcholinesterase (hAChE), butyrylcholinesterase (hBuChE), and monoamine oxidase-B (hMAO-B), with IC50 values of 4.8 μM, 13.7 μM, and 1.11 μM, respectively. This compound also demonstrates a high affinity for σ1 and σ2 receptors, with Ki values of 42.8 nM and 191 nM, respectively. AChE/BuChE/MAO-B-IN-1 is potentially useful in research focused on Alzheimer's disease and related neurological disorders. -
eeAChE/eqBuChE Inhibitor
eeAChE/eqBuChE-IN-1 is a reversible dual inhibitor targeting both eeAChE and eqBuChE, with IC50 values of 1.3 μM and 0.81 μM, respectively. This compound demonstrates significant anti-inflammatory activity and offers neuroprotective effects, particularly in mitigating Aβ25-35-induced cytotoxicity in PC12 cells. It is suitable for research applications focused on neurodegenerative diseases and related pathways. -
AChE Inhibitor
AChE-IN-31 is a non-competitive inhibitor of acetylcholinesterase (AChE). This compound demonstrates significant potential in the exploration of Alzheimer's disease pathology by modulating cholinergic signaling. AChE-IN-31 is suitable for use in research applications aimed at understanding the mechanisms of neurodegeneration and developing therapeutic strategies for cognitive disorders. -
AChE Inhibitor
AChE-IN-71 is an acetylcholinesterase (AChE) inhibitor that plays a significant role in the modulation of neurotransmitter levels. This compound is particularly relevant for research focused on neurodegenerative disorders, including Alzheimer’s disease. By inhibiting AChE activity, AChE-IN-71 can help elucidate the mechanisms underlying cholinergic dysfunction in Alzheimer's pathology, providing valuable insights for potential therapeutic strategies. -
AChE/BuChE Inhibitor
Feralolide is a dihydroisocoumarin that functions as a dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), exhibiting IC50 values of 55 μg/mL and 52 μg/mL, respectively. This compound also demonstrates antioxidant properties, effectively inhibiting 2,2-diphenyl-1-picrylhydrazyl (DPPH) and 2,2′-azinobis-3-ethylbenzothiazoline-6-sulfonic acid (ABTS). Feralolide may serve as a valuable tool in research focused on cognitive disorders, such as Alzheimer's disease, aiming to restore and enhance memory functions. -
Cholinesterase (ChE) Inhibitor
Echothiopate chloride is a potent, irreversible inhibitor of cholinesterase (ChE). By forming a covalent bond with the serine residue at the active site of ChE, it permanently inactivates the enzyme, necessitating de novo enzyme synthesis for restoration of activity. This long-lasting inhibition makes echothiopate chloride effective in ocular applications, particularly as a miotic agent in the management of chronic glaucoma and accommodative esotropia, with effects that can persist for over a week. -
AChE Inhibitor
Lycoramine is a dihydro-derivative of galanthamine that functions as a potent acetylcholinesterase (AChE) inhibitor. Isolated from the plant Lycoris radiata, it demonstrates significant potential in enhancing cholinergic signaling, making it a valuable reagent for research related to neurodegenerative diseases and cognitive disorders. Its inhibitory action on AChE may offer insights into therapeutic strategies for conditions such as Alzheimer's disease. -
Cholinesterase Inhibitor
AChE/BChE-IN-31 is a cholinesterase inhibitor targeting human acetylcholinesterase (hAChE) and equine butyrylcholinesterase (eqBChE). It demonstrates significant inhibitory activity against these enzymes, making it relevant for research on neurodegenerative diseases such as Alzheimer’s disease. Additionally, AChE/BChE-IN-31 exhibits antioxidant properties, with an IC50 value of 105.04 μM against DPPH, indicating its potential utility in studies related to oxidative stress. -
Cholinesterase Inhibitors; Lupane Derivative; Molecular Modeling; Triterpenoid
3β-Hydroxy-lup-20(29)-en-16-one is a potent dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), exhibiting a notable selectivity for BChE with an IC50 value of 28.9 μM. This lupane derivative serves as a valuable tool in the study of cholinergic signaling pathways and triterpenoid research. Its inhibitory properties position it as a potential candidate for neurodegenerative disease research applications, particularly in disorders characterized by cholinergic dysregulation. -
AChE/BChE Inhibitor
AChE/BChE-IN-24 is a potent inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), exhibiting IC50 values of 16.38 μM and 10.44 μM, respectively. This compound functions as a neuroprotective agent by preventing the breakdown of acetylcholine, thereby enhancing cholinergic neurotransmission. Its applications are particularly relevant in research related to neurodegenerative diseases and cognitive function disorders. -
AChE/BChE Inhibitor
Lakoochin C is a potent inhibitor of acetylcholinesterase (AChE) with an IC50 of 61.86 μM and butyrylcholinesterase (BChE) with an IC50 of 47.21 μM. This compound demonstrates significant biological activity in modulating cholinergic signaling, making it a valuable tool for research focused on neurodegenerative diseases such as Alzheimer's disease. Its application in studies of cholinergic dysfunction may provide insights into therapeutic strategies for memory-related disorders. -
AChE Inhibitor
AChE-IN-64 is a selective inhibitor of acetylcholinesterase (AChE) with an IC50 value of 36.9 µM. This compound is primarily utilized in research related to cognitive disorders, offering a valuable tool for the investigation of cholinergic dysfunction and its implications in conditions such as Alzheimer's disease and other neurodegenerative disorders. -
AChE Inhibitor
Quinolactacin A1 is a potent acetylcholinesterase (AChE) inhibitor derived from the solid-state fermentation of Penicillium citrinum 90648. It exhibits significant biological activity in inhibiting AChE, making it a valuable compound for studying neurodegenerative disorders, particularly Alzheimer's disease. Research applications include exploring therapeutic strategies and understanding the biochemical pathways associated with cholinergic dysfunction. -
AChE Inhibitor
Cyanofenphos is an orally active organophosphate compound that acts as an acetylcholinesterase (AChE) inhibitor, exhibiting neurotoxic properties. This reagent is associated with delayed neurotoxic effects, including ataxia and paralysis, and may present additional symptoms such as somnolence, decreased feed intake, and weight loss in avian models. Cyanofenphos demonstrates a self-antagonistic effect, whereby repeated low-dose pre-treatment can mitigate acute toxicity but exacerbate long-term neurotoxicity and decrease enzyme inhibition, with protective effects peaking 24 hours post-treatment. This compound is widely utilized in research focused on neurotoxicity and AChE inhibition pathways. -
BChE Inhibitor
BChE-IN-9 (Azepano-11-deoxo-glycyrrhetol) is a mixed type inhibitor of butyrylcholinesterase (BChE) with a Ki value of 0.21 µM. This compound exhibits significant inhibitory activity, making it a valuable tool for studying cholinergic signaling pathways and neurodegenerative diseases where BChE is implicated. Its use in research can provide insights into therapeutic strategies for conditions such as Alzheimer's disease and other neurocognitive disorders. -
AChE Inhibitor
AChE-IN-21 is a potent and selective inhibitor of acetylcholinesterase (AChE), exhibiting an IC50 value of 2.66 nM. This compound demonstrates significant blood-brain barrier permeability in vitro, making it suitable for central nervous system research applications. AChE-IN-21 may be utilized in studies related to neurodegenerative diseases, such as Alzheimer's disease, by modulating cholinergic signaling pathways. -
Acetylcholinesterase Inhibitor
Quilostigmine is a potent acetylcholinesterase inhibitor with an IC50 of 148 nM in rat brain acetylcholinesterase. This orally active analogue of Physostigmine demonstrates prolonged efficacy in reducing tremors. Its mechanism of action makes it a valuable tool for research related to Alzheimer's disease and other cognitive disorders. -
BChE Inhibitor
BChE-IN-4 is a potent butyrylcholinesterase (BChE) inhibitor that effectively crosses the blood-brain barrier. This compound has demonstrated the ability to attenuate learning and memory deficits associated with cholinergic deficits in mouse models. BChE-IN-4 shows promise for research applications related to Alzheimer's disease, making it a valuable tool for investigations into cognitive dysfunction and neurotransmitter modulation. -
BChE Inhibitor
Bleformin A is a potent butyrylcholinesterase (BChE) inhibitor with an IC50 value of 5.2 μM. Isolated from the natural source Bletilla striata, this compound demonstrates significant biological activity that is relevant to neurodegenerative disorders. Bleformin A is primarily utilized in research related to Alzheimer's disease, providing insights into cholinergic system modulation. -
Acetylcholinesterase Inhibitor, Butyrylcholinesterase Inhibitor
Melineurine is a reversible mixed-type inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), exhibiting IC50 values of 95.3 μM for AChE and 28.0 μM for BChE. This compound is instrumental in the study of neurodegenerative disorders, particularly Alzheimer's disease, due to its effects on cholinergic signaling. Melineurine serves as a valuable tool for investigating the role of cholinesterase inhibition in cognitive function and related therapeutic strategies. -
AChE Inhibitor
Fasciculin-II is a potent inhibitor of acetylcholinesterase (AChE), an enzyme critical for neurotransmitter regulation. By blocking AChE activity, Fasciculin-II enhances cholinergic transmission, making it a valuable tool for research in neurobiology and related fields. Its biological activity is particularly relevant in studies of synaptic function and neurodegenerative diseases. -
AChE/BChE/MAO-B Inhibitor
AChE/BChE/MAO-B-IN-1 is a reversible inhibitor targeting acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and monoamine oxidase B (MAO-B), exhibiting IC50 values of 7.31 μM, 0.56 μM, and 26.1 μM, respectively. This compound effectively crosses the blood-brain barrier and demonstrates neuroprotective properties while maintaining a lack of cytotoxicity. Its multifaceted inhibition profile makes it a valuable tool for research on neurodegenerative diseases and associated pathways. -
Dual MAO-AChE Inhibitor
MAO-A/B-IN-3 is a dual inhibitor targeting both monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B), as well as acetylcholinesterase (AChE). With IC50 values of 67 nM for MAO-A, 29 nM for MAO-B, and 1370 nM for AChE, this compound demonstrates substantial multi-target efficacy. MAO-A/B-IN-3 modifies key binding sites to enhance its inhibitory activity against MAO enzymes while reducing the impact on AChE. This reagent is particularly relevant for research focused on neurodegenerative disorders. -
Cholinesterase (ChE) Inhibitor
Dihydro Donepezil is a potent cholinesterase (ChE) inhibitor, serving as a metabolite of Donepezil. It demonstrates significant biological activity, inhibiting acetylcholinesterase with IC50 values of 8.12 nM for bovine acetylcholinesterase (bAChE) and 11.6 nM for human acetylcholinesterase (hAChE). This compound is primarily utilized in research focused on neurodegenerative disorders and cognitive enhancement, contributing to studies on Alzheimer's disease and related pathways. -
AChE Inhibitor
AChE-IN-52 is an acetylcholinesterase (AChE) inhibitor that demonstrates notable antitumor activity, particularly against breast cancer MCF-7 cells. This compound significantly disrupts amino acid metabolism and inhibits the migration of MCF-7 cells. Furthermore, AChE-IN-52 exerts its anticancer effects through the regulation of Best1 and HIST1H2BJ, making it a valuable tool for research in cancer biology and therapeutic development. -
AchE Inhibitor
1,10-Bis(pyridinium)decane is a biscationic compound that acts as an acetylcholinesterase (AchE) inhibitor, demonstrating an IC50 of 25.8 nM. This reagent is valuable for research focused on neuropharmacology and the modulation of cholinergic signaling. Its specificity for AchE makes it suitable for studies investigating cognitive function and neurodegenerative diseases. -
AChE Inhibitor
Ganstigmine hydrochloride is an orally active inhibitor of acetylcholinesterase (AChE) that enhances the release of soluble amyloid precursor protein alpha (sAPPα) from neuroblastoma cells. This compound has been shown to increase acetylcholine levels in the prefrontal cortex of rats, making it a valuable tool in the study of cholinergic signaling. Ganstigmine hydrochloride is primarily utilized in research focused on neurological disorders, particularly Alzheimer's disease, to explore its implications in cognitive function and neuroprotection.
